Phase 3 Readout~month

Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi

Indication
Irritable Bowel Syndrome With Constipation (IBS-C)

Other upcoming events for ARDX

Phase 3 ReadoutPhase 3 Topline: A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and
Phase 3 ReadoutPhase 3 Topline: An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With
Phase 3 ReadoutPhase 3 Topline: An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With
Patent ExpiryPatent/Exclusivity Expiry: XPHOZAH
Patent ExpiryPatent/Exclusivity Expiry: IBSRELA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi — ARDX Phase 3 Readout | BioSniper